ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell?

Amneal Pharmaceuticals said the FDA approved its ready-to-use romidepsin injection solution (27.5 mg/5.5 mL) in single-dose vials. The drug received Competitive Generic Therapy (CGT) designation, granting Amneal 180 days of market exclusivity. Amneal said the product references a Teva romidepsin liquid previously withdrawn. IQVIA data cited about $78 million in U.S. sales for the prior lyophilized form.

Amneal Pharmaceuticals said the U.S. FDA approved its romidepsin injection solution (27.5 mg/5.5 mL) in single-dose, ready-to-use vials. The product is eligible for Competitive Generic Therapy status, granting 180 days of market exclusivity, and references a former Teva formulation. IQVIA data cited by Amneal put U.S. sales of romidepsin lyophilized powder at about $78 million for 12 months ended April 2026.

ANI Pharmaceuticals (NASDAQ: ANIP) stockholders approved all proposals at their 2026 Annual Meeting, including the election of seven directors, ratification of Ernst & Young LLP as auditor, and advisory approval of executive compensation. They also approved the Amended and Restated 2022 Stock Incentive Plan and opted for annual advisory votes on executive pay. The meeting's results, detailing voting figures for each proposal, reinforce investor confidence in the company's governance and compensation practices.

Zacks Research has upgraded ANI Pharmaceuticals (NASDAQ:ANIP) from a "hold" to a "strong-buy" rating, despite recent insider selling. Analysts currently maintain a "Moderate Buy" consensus with a target price of $107.33, though Guggenheim recently raised its target to $124. The stock opened at $78.07, and institutional investors have also adjusted their positions in the company.

ANI Pharmaceuticals has announced the launch of Carbamazepine Extended-Release Capsules, 100 mg, 200 mg, and 300 mg, a generic version of Carbatrol®. This launch strengthens ANI's Generics portfolio and aims to improve patient access to essential medicines. The U.S. annual sales for this product are approximately $65 million based on recent IQVIA data.

ANI Pharmaceuticals (ANIP) has launched Carbamazepine Extended-Release Capsules in 100 mg, 200 mg, and 300 mg strengths, a generic version of Carbatrol. This launch targets a U.S. market with approximately $65 million in annual sales, aiming to strengthen ANI's generics portfolio and improve patient access to essential medicines. The company highlights its commitment to quality and compliance while expanding in this limited-competition segment.